The Pruritus drugs in development market research report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pruritus. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pruritus and features dormant and discontinued products.

GlobalData tracks 59 drugs in development for Pruritus by 61 companies/universities/institutes. The top development phase for Pruritus is preclinical with 22 drugs in that stage. The Pruritus pipeline has 56 drugs in development by companies and three by universities/ institutes. Some of the companies in the Pruritus pipeline products market are: Amgen, Maruho and Lumosa Therapeutics.

The key targets in the Pruritus pipeline products market include Kappa Type Opioid Receptor (KOR1 or OPRK or OPRK1), Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1), and Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1).

The key mechanisms of action in the Pruritus pipeline product include Kappa Type Opioid Receptor (KOR1 or OPRK or OPRK1) Agonist with ten drugs in Pre-Registration. The Pruritus pipeline products include ten routes of administration with the top ROA being Oral and eight key molecule types in the Pruritus pipeline products market including Small Molecule, and Monoclonal Antibody.

Pruritus overview

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin, and reactions to drugs. Symptoms include redness, bumps, spots or blisters, dry, cracked skin, and leathery or scaly texture to the skin. Risk factors include heat, allergies, asthma, hay fever, hives, and eczema. Treatment includes corticosteroids, antihistamines, and antidepressants.

For a complete picture of Pruritus’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.